Different NIPTs for different patient needs
No other genetic testing laboratory currently offers as much expertise, experience, and choice in NIPT—noninvasive prenatal testing, also called NIPS or cfDNA (cell-free DNA) screening.
With the 2016 acquisition of Sequenom, creator of the first commercially available NIPT, Integrated Genetics now offers two NIPTs—with more than 1 million tests run in total.
Each NIPT offers different capabilities and/or panels to suit the specific needs of your patients and your practice.
The only clinically validated genome-wide NIPT, screens all 23 chromosome pairs, reporting aneuploidies, large deletions and duplications greater than 7 Mb in addition to select microdeletions; after more than 35,000 tests resulted, more than 29% of all positive findings were only detectable using genome-wide cfDNA, the methodology used by MaterniT GENOME, as compared to traditional NIPT.1
The pioneering NIPT with more than 1 million tests run; screens the core trisomies 21, 18, and 13, and (optionally) fetal sex, clinically relevant microdeletions, sex chromosome aneuploidies, and trisomies 16 and 22.
Upgraded MaterniT specimen collection kit
The upgraded MaterniT specimen collection kit features new branding for better kit identification and fewer components – including one 10 mL Streck tube instead of two – for improved ease-of-use.
If you’ve not had a test and have questions about costs or coverage, use our estimator.
If you have already had a test performed, we can help answer questions about results.
Ask questions about genetic testing options or results, or schedule an appointment.
- Ehrich M, Tynan J, Mazloom A, Almasri E, McCullough R, Boomer T, et al. Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases. Genet Med. 2017 Jun 15. 1-6.